Overview

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)

Status:
Withdrawn
Trial end date:
2023-05-01
Target enrollment:
0
Participant gender:
All
Summary
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722) to evaluate the duration of treatment response, disease progression, and survival status up to 5 years after the inclusion.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Asan Medical Center
Treatments:
Dasatinib
Imatinib Mesylate
Criteria
Inclusion Criteria:

- Patients who were newly diagnosed as chronic phase chronic myelogenous leukemia, were
enrolled to 'IDEAL study (A Phase IV Study to Evaluate Efficacy and Safety of
Imatinib(Glinib®) 600mg/day Depending on Early Molecular Response in Newly Diagnosed
Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722)

- Subjects who agreed with the participation of this study after informed consent

Exclusion Criteria:

- Patients who were newly diagnosed as chronic phase chronic myelogenous leukemia, agree
with the participation to 'IDEAL study (A Phase IV Study to Evaluate Efficacy and
Safety of Imatinib(Glinib®) 600mg/day Depending on Early Molecular Response in Newly
Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722) after
informed consent, but were excluded finally from the 'IDEAL' study